JPRN-jRCT2080220559
Unknown
Phase 2
ate Phase II study of Paricalcitol injection
Abbott Japan Co., Ltd.0 sitesMay 19, 2008
ConditionsSecondary Hyperparathyroidism
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Secondary Hyperparathyroidism
- Sponsor
- Abbott Japan Co., Ltd.
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged 20 or over
- •Chronic kidney disease subjects receiving hemodialysis with secondary hyperparathyroidism
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Phase II clinical research study evaluating the effectiveness of paricalcitol in combination with gemcitabine/nab-paclitaxel in patients with advanced pancreatic cancer.Advanced pancreatic cancer.MedDRA version: 21.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-000073-24-IECancer Trials Ireland43
Active, not recruiting
Not Applicable
The PRIMO II Study: Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5 - PRIMO IIStage 5 Chronic Kidney Disease (CKD) in subjects receiving hemodialysis who haveleft ventricular hypertrophy (LVH).MedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseMedDRA version: 9.1Level: LLTClassification code 10049773Term: Left ventricular hypertrophyEUCTR2007-005092-33-CZAbbott GmbH & Co. KG220
Active, not recruiting
Not Applicable
The PRIMO II Study: Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5 - PRIMO IIStage 5 Chronic Kidney Disease (CKD) in subjects receiving hemodialysis who haveleft ventricular hypertrophy (LVH).MedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseMedDRA version: 9.1Level: LLTClassification code 10049773Term: Left ventricular hypertrophyEUCTR2007-005092-33-GBAbbott GmbH & Co. KG220
Active, not recruiting
Not Applicable
The PRIMO II Study: Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5 - PRIMO IIEUCTR2007-005092-33-GRAbbott GmbH & Co. KG220
Active, not recruiting
Not Applicable
The PRIMO II Study: Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5.Estudio Primo II : Beneficios de Paricalcitol inyectable sobre la morbilidad cardíaca provocada por la insuficiencia renal en los sujetos con enfermedad renal crónica en estadio 5. - PRIMO IIEUCTR2007-005092-33-ESAbbott GmbH & Co. KG220